On this week’s Biotech Hangout, hosts Josh Schimmer, Brad Loncar, Sam Fazeli and Tess Cameron kick off the show digging into some macro trends and the potential of an incoming M&A wave. The conversation then turns to a range of topics related to China, including the impact of the stimulus, recent innovation, and the latest obesity assets & China-sourced drugs. The hosts also discuss the updates coming out of Roche’s business day, including
the company’s acquisition of a CDK inhibitor from China’s Regor. On the data front, the hosts discuss Poseida and Roche’s myeloma data and J&J / Legend’s Carvytki data, then turn to other news of the week including J&J’s battle to implement a 340B rebate model, BioNTech & Instadeep AI Day updates, IGM Biosciences pivots to immunology, Harrow relaunches Triesence, and more. *This episode aired on October 4, 2024.
Podden och tillhörande omslagsbild på den här sidan tillhör Daphne Zohar, Josh Schimmer, Brad Loncar, Tim Opler & more. Innehållet i podden är skapat av Daphne Zohar, Josh Schimmer, Brad Loncar, Tim Opler & more och inte av, eller tillsammans med, Poddtoppen.
